SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like Glytec Nabs Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software August 15, 2017 7 Key Products That Could Help Dig Valeant Out of Its Hole January 9, 2018 3rd Stemline Patient Died in Clinical Trial One Day Before $45 Million Public Offering February 1, 2017
Glytec Nabs Fourth FDA 510(k) Clearance for Its Market-Leading Diabetes Therapy Management Software August 15, 2017
3rd Stemline Patient Died in Clinical Trial One Day Before $45 Million Public Offering February 1, 2017